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Selective Expression of Chemokine Monokine Induced
by Interferon-c in Alopecia Areata
To the Editor:
Alopecia areata (AA) is a dis¢guring disease characterized by
nonscarring hair loss. The ¢nding that AA can be transferred to
human scalp explants on severe combined immunode¢cient
(SCID) mice by injecting scalp-in¢ltrating T lymphocytes indi-
cates that AA is a tissue-restricted autoimmune disease (Gilhar
et al, 1998). The putative autoantigen has not yet been identi¢ed.
Histopathology shows perifollicular and intrafollicular in£amma-
tion of anagen hair bulbs, whereas telogen stage hair follicles
remain una¡ected. Locally in¢ltrating CD4þ and CD8þ lym-
phocytes have been implicated as e¡ector cells being responsible
for the reversible alteration of the hair follicle and the resulting
hair loss (McDonagh and Messenger, 2001; McElwee and Ho¡-
mann, 2002). In¢ltrating leukocytes are mainly distributed
around the hair bulb up to the level of the sebaceous glands.
Nevertheless, the expression pattern of chemoattractants guiding
the leukocytes to sites of evolving AA has not been studied in
detail yet. We therefore analyzed the expression of chemokines
presumably leading to recruitment of mononuclear cells such
as interferon-inducible protein-10 (IP-10), monocyte chemoat-
tractant protein-1 (MCP-1), monokine induced by interferon-g
(MIG), macrophage in£ammatory proteins a and b (MIP-1a and
b), and growth-related oncogene-a (GROa) by in situ hybridiza-
tion.
Para⁄n-embedded biopsies of 13 AA patients, which had been
obtained for routine histopathologic workup, were processed for
mRNA in situ hybridization as previously described (Gillitzer
et al, 1993) using 35S-labeled antisense probes. The cDNA probes
used were provided byT. Yoshimura (NCI, Fredrick, MD; MCP-
1),T. Schall (DNAX, Palo Alto, CA; MIP-1b), Genetics Institute
(Cambridge, MA; MIP-1a), J.M. Farber (National Institute of Al-
lergy and Infectious Diseases, Bethesda, MD; MIG), R. Kulke
(University of Kiel, Kiel, Germany; IP-10), and A. Anisowicz
(Dana Farber Cancer Institute, Boston, MA; GROa). Addition-
ally, serial sections were immunohistochemically labeled with
leukocyte-speci¢c mouse antibodies against CD3 (Becton Dick-
inson, Sunnyvale, CA), CD4, or CD68 (Dako, Hamburg, Ger-
many) to correlate chemokine mRNA expression with spatial
distribution of mononuclear leukocyte subtypes. Immunohisto-
chemistry was performed using a three-step streptavidin^biotin^
peroxidase procedure as described (Gillitzer et al, 1993).Thereafter,
slides were evaluated by two independent investigators. Both
localization and intensity of chemokine mRNA expression
were documented and semiquantitatively graded as ‘‘no,’’ ‘‘weak,’’
‘‘moderate,’’ or ‘‘strong’’ expression. Previously characterized skin
lesions of psoriasis patients with a distinct expression pattern and
distribution of chemokines (Gillitzer et al, 1993; Goebeler et al,
1998) served as internal controls.
Among the chemokines investigated we detected a strong ex-
pression of MIG mRNA, a moderate expression of MCP-1, and a
weak expression of IP-10 mRNA, whereas all other chemokines
(GROa, MIP-1a and MIP-1b) were not expressed at signi¢cant
levels. The chemokine expression pro¢les of all patients are sum-
marized in Table I. In most samples, MIG mRNA was mainly
found in mononuclear cells, most likely monocytes/macro-
phages, in the peri- and intrabulbar in¢ltrate as well as in the
follicular papilla (Fig 1a,b). In these sections, MIG mRNA ex-
pression spatially strongly correlated with an in¢ltrate mainly
composed of CD3þ , CD4þ , and CD8þ lymphocytes (Fig
1e^g) and some intermingled CD68þ macrophages. Interest-
ingly, only a weak intrabulbar leukocyte in¢ltration was observed
in cases lacking MIG expression. In one biopsy, MIG mRNA
expression was also detected in the medulla of the hair shaft
(Fig 1c,d).
In contrast to MIG, MCP-1 mRNA showed a completely dif-
ferent distribution pattern with expression by keratinocytes of the
inner root sheath but only weak expression around the hair folli-
cles (Fig 1h,i). As outlined inTable I, chemokine expression pat-
terns did not appear to correlate with clinical severity and criteria
de¢ned by the National Alopecia Areata Foundation (Olsen et al,
1999) such as extent of hair loss, number of AA episodes, or pre-
sence of associated diseases.
In this study, we elucidated the chemokine pro¢le presumably
being responsible for recruitment of mononuclear leukocytes in
AA. The chemokine found to be most prominently expressed
was the lymphocyte-speci¢c chemoattractant MIG. Correspond-
ing to its expression, a lymphocyte-dominated, mainly perifolli-
cular in¢ltrate was detected. In addition, moderate levels of
MCP-1 mRNAwere observed whereas mRNA expression of all
the other chemokines investigated was low (IP-10) or negligible
(GROa, MIP-1a, and b). The expression variability of individual
chemokines, with, however, a strong tendency of MIG and
MCP-1 expression, does not appear to be a particular feature of
AA and has been described in many other in£ammatory skin dis-
orders (Ritter et al, 1996; Goebeler et al, 1998; Spandau et al, 1998;
Goebeler et al, 2001).
The chemokine expression pattern of AA is dominated by the
Th1-related interferon-g-inducible expression of MIG and, to a
lesser extent, of IP-10, which argues for a persistingTh1 response.
This is in line with reports describing expression of interferon-
g-inducible molecules such as the MX1 gene product in AA
(Tazi-Ahnini et al, 2000; Gilhar et al, 2003). Di¡erences in MIG
expression intensity as well as variable patterns of the other che-
mokines may also correspond to distinct stages of in£ammation
as recently postulated in a mouse model of AA (Carroll et al,
2002). Interestingly, MIP-1awhich was not found to be expressed
in 10 of the 11 AA cases, is highly abundant in di¡use cutaneous
leishmaniasis, a local in£ammatory condition with de¢ciencies of
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Th1 e¡ector cells (Ritter et al, 1996). In contrast, chemokine pro-
¢les with strong expression of MIG accompanied by a moderate
expression of MCP-1 had been described in other Th1-related
skin diseases such as lichen planus (Spandau et al, 1998) and aller-
gic contact hypersensitivity (Goebeler et al, 2001).
Regarding leukocyte in¢ltration in AA, the following scenario
might be feasible: Owing to as yet unknown events, autoreactive
T-helper lymphocytes interacting with their putative autoantigen
in the anagen hair follicle induce MCP-1 expression by keratino-
cytes, which then supports recruitment of additional T lympho-
cytes and monocytes/macrophages to the immediate vicinity thus
focusing the in£ammatory reaction around the hair bulb. In turn,
the latter are furthermore stimulated by interferon-g-producingT
cells to synthesize MIG and, to a lesser extent, IP-10, which both
perpetuate recruitment of lymphocytes, thus promoting an on-
going in£ammatory reaction.
In conclusion, the increased expression of MIG and MCP-1
refers to an important role of these chemokines during the course
of AA, which appears to re£ect the distribution of e¡ector cells.
Therefore, inhibition of the target chemokines MIG and MCP-1
may be a reasonable strategy for a preferably local anti-in£amma-
tory therapy of AA.
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Figure1. Spatial distribution of chemokine
mRNA expression in hair follicles of AA.
(a^e, h, i) In situ hybridization with [35S]UTP-
labeled MIG or MCP-1 antisense probes (f, g)
immunohistochemistry for lymphocyte mar-
kers. (a, b) longitudinal sections; (c^i) transversal
sections. (a, b, e) MIG mRNA is expressed in
the perifollicular in¢ltrate and the dermal papilla.
( f, g) Immunohistochemistry performed on se^
rial sections of (e) shows CD3þ ( f ) and CD8
þ lymphocytes (g) at sites of MIG expression.
(c, d) MIG mRNA is expressed perifollicularly
as well as in the medulla of the hair shaft. (h, i)
MCP-1 mRNA is detectable in the inner root
sheath. (a, c, e, h) Bright-¢eld illumination; (b,
d, i) dark-¢eld illumination of corresponding
sites, which allows better identi¢cation of silver
grain signals. Bar, 100 mm.
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Table I. Chemokine mRNA expression in AA
Patient
1 2 3 4 5 6 7 8 9 10 11 12 13
mRNA expressiona
GROa þ  ND  ND        
IP-10     þ     þ  þ þ
MCP-1 þ þ  þ þ þ þ   þ þ þ   þ 
MIG   þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ 
MIP-1a  ND þ ND         
MIP-1b ND   ND ND     ND ND ND ND
Sexb M F M F F F F M F F M F M
Age at onset of ¢rst episode (years) 29 28 31 57 18 33 6 26 33 36 43 33 45
Number of episodes 2 2 1 1 3 1 ND 2 3 1 1 ND 1
Age at onset of current episode (years) 38 30 31 57 31 33 31 26 35 36 43 36 45
Duration of current episode (months)c 12 2 4 2 18 6 36 2 16 2 2 3 20
Extent of hair loss of current episodec,d S3B0N0 S1B0N0 S3B1N1 S4B0N0 S4B1N1 S2B0N0 S3B1N1 S1B0N1 S4B1N1 S1B0N0 S3B1N0 S2B0N0 S4B0N0
Medical historye  AR, HT AD, AR DHD  A, AD  AD, AR AD, AR CD AR HT HT
amRNA expression intensity was semiquantitatively graded as no (^), weak (þ ), moderate (þ þ ), or strong (þ þ þ ). ND, not done.
bF, female; M, male.
cAt time point of skin biopsy.
dAccording to the ‘‘Alopecia Areata Investigational Assessment Guidelines’’ (Olsen et al, 1999).
eA, asthma; AD, atopic dermatitis; AR, allergic rhinitis; CD, Crohn’s disease; DHD, dermatitis herpetiformis Duhring; HT, Hashimoto’s thyreoiditis.
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